Insulet (NASDAQ:PODD) Price Target Raised to $317.00 at Morgan Stanley

Insulet (NASDAQ:PODD) had its price objective hoisted by Morgan Stanley from $234.00 to $317.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has an overweight rating on the medical instruments supplier’s stock.

A number of other brokerages have also recently issued reports on PODD. Raymond James boosted their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. UBS Group increased their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Barclays boosted their price objective on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Sanford C. Bernstein began coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Trading Down 2.9 %

Shares of PODD opened at $261.16 on Monday. The stock’s fifty day simple moving average is $236.86 and its 200-day simple moving average is $206.85. Insulet has a 12-month low of $160.19 and a 12-month high of $279.40. The firm has a market capitalization of $18.32 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently modified their holdings of the business. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC purchased a new position in Insulet in the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC lifted its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its stake in Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.